Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

ABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, co...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jung Sun Kim, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Cancer Medicine
Subjects:	advanced HCC immune checkpoint inhibitor Nivolumab monotherapy Nivolumab plus ipilimumab organ‐specific objective response rate prior ICI treatment
Online Access:	https://doi.org/10.1002/cam4.70997
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
by: Hiroshi Sawayama, et al.
Published: (2022-12-01)

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations
by: Celeste Vallejo, et al.
Published: (2025-03-01)

Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven‐Year‐Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review
by: Aziz Eghbali, et al.
Published: (2025-08-01)

Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases
by: Chika Nagahisa, et al.
Published: (2025-08-01)

Nivolumab-induced interstitial lung disease in the patient with melanoma
by: Marcin Morawski, et al.
Published: (2024-02-01)

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01)

Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01)

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
by: Young Kwang Chae, et al.
Published: (2025-08-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
by: D. D. Ivanova, et al.
Published: (2024-12-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report
by: Shunji Endo, et al.
Published: (2020-10-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
by: Omer Faruk Kuzu, et al.
Published: (2025-07-01)

Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
by: M.S. Ruban, et al.
Published: (2025-03-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
by: Xinming Lei, et al.
Published: (2024-11-01)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
by: Elisa Gozzi, et al.
Published: (2020-05-01)

Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
by: Maral Martin Mildanoglu, et al.
Published: (2025-07-01)

Nivolumab in real-life clinical practice
by: M. A. Lyadova, et al.
Published: (2019-12-01)

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy
by: Yu-ying Lei, et al.
Published: (2025-08-01)

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report
by: Nidhi Kuchimanchi, et al.
Published: (2025-07-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01)

Discordant Response to Nivolumab Plus Ipilimumab and Identification of BRAF V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case Report
by: Olivia Wilkins, DO, et al.
Published: (2025-05-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: Drew M Pardoll, et al.
Published: (2020-10-01)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
by: David Anson, et al.
Published: (2019-01-01)

The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma
by: A. V. Ignatova, et al.
Published: (2024-06-01)

A novel approach to overcome black box of AI for optical diagnosis in colonoscopy
by: Youmin Shin, et al.
Published: (2025-07-01)

Surgical technique for secondary pectoralis major transfer after reverse total shoulder arthroplasty to treat residual internal rotation dysfunction
by: Chang Hee Baek, et al.
Published: (2024-12-01)

EFFICACY OF DIFFERENT TACTICS FOR INITIAL ANTIHYPERTENSIVE THERAPY
by: O. A. Pleyko, et al.
Published: (2015-12-01)

COMPARISON OF DIFFERENT STRATEGIES OF ANTIHYPERTENSIVE THERAPY IN OUT-PATIENT CLINIC
by: O. A. Plejko, et al.
Published: (2016-01-01)

Latanoprost in the treatment of primary open-angle glaucoma
by: S. Yu. Petrov, et al.
Published: (2024-12-01)

Prediction of Flexural Capacity of RC Beams Strengthened in Flexure with FRP Fabric and Cementitious Matrix
by: Kyusan Jung, et al.
Published: (2015-01-01)

Rapid Equipment-Free Nucleic Acid Extraction Using a Silica-Based Pipet Tip Column
by: Chaewon Jung, et al.
Published: (2025-05-01)

Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck
by: L. V. Bolotina, et al.
Published: (2020-07-01)

Quantitative and Qualitative Evaluation of Antibiotic Consumption in Urological Pathology
by: Mihai Cornel TĂMĂŞAN, et al.
Published: (2025-05-01)

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
by: Pavlos Msaouel, et al.
Published: (2025-01-01)